In Brief: Ortec International
This article was originally published in The Gray Sheet
Executive Summary
Ortec International: "Successfully defends" U.S. patent on its Composite Cultured Skin biologically active skin replacement against a re-examination procedure initiated by competitor Organogenesis in February 1994, the firm reports. On Dec. 10, the U.S. patent office reissued Ortec's CCS patent "with modifications which do not substantially change the scope of the original patent," the company says. Ortec is conducting U.S. clinical trials at five centers to support a premarket approval application for the full-thickness skin replacement ("The Gray Sheet" April 29, I&W-7)...